“First up is putting a stop to PBM compensation being tied to the sticker price of the drug, is causing these middlemen to often favor higher prices drugs. The incentive of PBMs is just wrong. They win when prices are higher, not lower. Today’s proposals will flip that on its head. Another set of provisions will shine the light on PBMs that have been operating in the shadows for years.”